Why liver screening belongs in routine diabetes care
“If you saw 11 patients with type 2 diabetes last week and you did not diagnose one with advanced fibrosis, you probably missed it.”
— Professor Fernando Bril, University of Alabama at Birmingham
Around two-thirds of people with type 2 diabetes or obesity have excess fat in the liver, and roughly 15 per cent already have clinically significant fibrosis. Yet it often goes undetected: there are usually no symptoms, and liver enzymes can appear normal well into the disease.
In this 25-minute conversation, Professor Bril joins Dr Gary Deed, GP and Chair of the RACGP Diabetes Specific Interests group, to discuss:
- Who should be screened, and why type 2 diabetes is the highest-risk group
- Using FIB-4 as the first-line test, interpreting the cut-offs, and avoiding age-related pitfalls
- Next steps for an indeterminate result, including where elastography and the ELF test fit
- Managing the whole metabolic picture, including the safe use of statins